Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q1 2025 Earnings Report

Bicara Therapeutics logo
$13.70 +0.66 (+5.06%)
As of 05/14/2025 04:00 PM Eastern

Bicara Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.40
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Bicara Therapeutics' Q2 2025 earnings is scheduled for Thursday, June 26, 2025

Bicara Therapeutics Earnings Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat